MLTX Insider Ramnik Xavier Buys 22,195 Shares

Ramnik Xavier Buys MoonLake Immunotherapeutics Stock

Ramnik Xavier picked up 22,195 shares of MoonLake Immunotherapeutics, trading on the NasdaqCM under the ticker MLTX, on June 17, 2026. This transaction sits alongside a busy period of executive and director trading at the clinical-stage biotechnology firm, drawing attention to how internal stakeholders are managing their holdings.

Recent Insider Activity at MoonLake Immunotherapeutics

The mid-June filing period brought multiple transactions across the leadership team. On June 17, 2026, alongside the acquisition by Xavier, several other individuals also added 22,195 shares each, including Phillips Andrew John, Spike Loy, and Catherine Moukheibir. On the same day, Chief Financial Officer Matthias Bodenstedt sold 15,082 shares at an average price of $19.68 in a planned transaction valued at $296,813.76. Bodenstedt followed this with a second planned sale on June 18, 2026, offloading 2,794 shares at $19.60 for a total of $54,762.40. Earlier in the month on June 16, 2026, Chief Scientific Officer Kristian Reich parted with 50,000 shares at an average price of $18.70 under a pre-arranged schedule, bringing in $935,000.

MoonLake Immunotherapeutics Stock Price Performance

MLTX shares changed hands at $22.38. The equity moves between a 52-week low of $5.95 and a peak of $62.75. The 50-day moving average sits at $16.51 while the 200-day moving average rests near $16.88. The company holds a market capitalization of roughly $1.07 billion.

Analysts Set New Price Targets

Wall Street firms keep a close watch on the biotechnology company with a consensus buy recommendation. On July 1, 2026, Leerink Partners maintained an outperform rating and lifted its target to $29.00 from $24.00. Later in the summer, HC Wainwright & Co. maintained its buy rating on August 13, 2026, setting a $50.00 target, and later reiterated that buy stance on October 5, 2026. Across thirteen analyst opinions, the mean price target lands at $28.54, with targets stretching from a low of $6.00 up to a high of $50.00.

Focus on Biotechnology Innovations

Headquartered in Zug, Switzerland, MoonLake Immunotherapeutics develops treatments for inflammatory skin and joint diseases. The firm builds therapies around Sonelokimab, a tri-specific nanobody targeting inflammatory conditions in dermatology and rheumatology, addressing ailments like psoriatic arthritis and hidradenitis suppurativa.

Looking Ahead for MLTX

Investors tracking the company will note that the next financial updates are slated for November 5, 2026. Market participants continue to evaluate both insider transaction reports and upcoming clinical milestones to measure the firm's operational progress.